{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:41:02Z","timestamp":1786549262020,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) carries substantial risks of venous thromboembolism (VTE), pathological fractures, acute kidney injury (AKI), and death. Statins possess anti-inflammatory, immunomodulatory, and anti-thrombotic properties that may reduce these complications, yet their associations with several key MM outcomes have not been evaluated simultaneously in a single real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the association between post-diagnosis statin exposure and 5-year all-cause mortality, VTE, pathological fractures, and AKI in MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study in the TriNetX Linked network (query date: 16 January 2026). Adults with MM were classified by statin exposure on or after diagnosis. We applied 1:1 propensity score matching on 59 baseline covariates. Outcomes were assessed from day 1 through 5\u00a0years using Kaplan\u2013Meier methods and Cox proportional hazards models. To assess robustness to unmeasured confounding,\n                      <jats:italic toggle=\"yes\">E<\/jats:italic>\n                      -values were calculated for effect estimates and their confidence interval (CI) limits.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 43\u00a0543 adults with MM, 8756 had post-diagnosis statin exposure. After matching, 7167 patients remained in each cohort with strong covariate balance. Statin exposure was associated with lower 5-year mortality [17.5% vs. 26.0%; hazard ratio (HR)\u00a0=\u00a00.591, 95% CI: 0.549\u20130.635], VTE (9.2% vs. 12.0%; HR\u00a0=\u00a00.688, 95% CI: 0.617\u20130.767), and pathological fractures (4.6% vs. 7.6%; HR\u00a0=\u00a00.541, 95% CI: 0.469\u20130.623). AKI risk was similar in absolute terms (19.3% vs. 19.7%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.606), although time-to-event analysis identified a modest hazard reduction (HR\u00a0=\u00a00.900, 95% CI: 0.825\u20130.981). Findings were robust to unmeasured confounding based on\n                      <jats:italic toggle=\"yes\">E<\/jats:italic>\n                      -values.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this propensity score-matched electronic health record cohort study, statin exposure after MM diagnosis was associated with improved 5-year survival and fewer VTEs and pathological fractures, with a modest time-to-event benefit for AKI. Prospective studies should evaluate statin initiation as an adjunct strategy in MM management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005281","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:05:36Z","timestamp":1783011936000},"page":"4854-4865","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6291-333X","authenticated-orcid":false,"given":"Naveen","family":"Gautam","sequence":"first","affiliation":[{"name":"Gulmi Durbar Basic Hospital, Gulmi, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2657-643X","authenticated-orcid":false,"given":"Krishna","family":"Kandel","sequence":"additional","affiliation":[{"name":"General Practice and Emergency Medicine Department, Matrishishu Miteri Provincial Hospital, Pokhara, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7885-3416","authenticated-orcid":false,"given":"Jyoti","family":"Sharma","sequence":"additional","affiliation":[{"name":"Nepal Police Hospital, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"R1-20260812","first-page":"506\u201313","article-title":"Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish Myeloma registry","volume":"103","author":"Blimark","year":"2017","journal-title":"Haematologica"},{"key":"R2-20260812","first-page":"482\u201390","article-title":"Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry","volume":"36","author":"Courant","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R3-20260812","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.clml.2019.09.052","article-title":"Fractures and survival in multiple myeloma: results from a population-based study","volume":"19","author":"Thorsteinsdottir","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R4-20260812","doi-asserted-by":"crossref","first-page":"4991\u201398","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"R5-20260812","doi-asserted-by":"crossref","first-page":"2516\u201320","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"R6-20260812","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"R7-20260812","doi-asserted-by":"crossref","first-page":"29\u201337","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"R8-20260812","doi-asserted-by":"crossref","first-page":"1640\u201350","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"key":"R9-20260812","doi-asserted-by":"crossref","first-page":"4008\u201314","DOI":"10.1200\/JCO.2016.68.3482","article-title":"Statins are associated with reduced mortality in multiple myeloma","volume":"34","author":"Sanfilippo","year":"2016","journal-title":"J Clin Oncol"},{"key":"R10-20260812","doi-asserted-by":"crossref","first-page":"796\u2013808","DOI":"10.1038\/s41375-020-0962-2","article-title":"The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma","volume":"35","author":"Longo","year":"2021","journal-title":"Leukemia"},{"key":"R11-20260812","doi-asserted-by":"crossref","first-page":"2497\u2013509","DOI":"10.1158\/2767-9764.CRC-23-0350","article-title":"Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors","volume":"3","author":"Juarez","year":"2023","journal-title":"Cancer Res Commun"},{"key":"R12-20260812","doi-asserted-by":"crossref","first-page":"652\u201361","DOI":"10.1002\/ajh.25778","article-title":"Statin use is associated with improved survival in multiple myeloma: a Swedish population-based study of 4315 patients","volume":"95","author":"Br\u00e5nvall","year":"2020","journal-title":"Am J Hematol"},{"key":"R13-20260812","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.1016\/j.clml.2020.02.011","article-title":"Receipt of statins is associated with lower risk of multiple myeloma: systematic review and meta-analysis","volume":"20","author":"Ponvilawan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R14-20260812","doi-asserted-by":"crossref","first-page":"1203\u201310","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality","volume":"4","author":"Schoen","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"R15-20260812","first-page":"100081","article-title":"Revised strengthening the reporting of cohor, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R16-20260812","doi-asserted-by":"crossref","first-page":"554\u201367","DOI":"10.1016\/j.ctrv.2015.04.005","article-title":"Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"41","author":"Zhong","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R17-20260812","doi-asserted-by":"crossref","first-page":"3566\u201375","DOI":"10.1182\/bloodadvances.2024015287","article-title":"Statin use and survival in CLL\/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials","volume":"9","author":"Abuhelwa","year":"2025","journal-title":"Blood Adv"},{"key":"R18-20260812","doi-asserted-by":"crossref","first-page":"1886\u201397","DOI":"10.1158\/1535-7163.MCT-06-0745","article-title":"Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma","volume":"6","author":"Wong","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"R19-20260812","doi-asserted-by":"crossref","first-page":"3354\u201362","DOI":"10.1182\/blood-2003-03-0970","article-title":"Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels","volume":"102","author":"van de Donk","year":"2003","journal-title":"Blood"},{"key":"R20-20260812","first-page":"1053\u201363","article-title":"Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells","volume":"11","author":"Otsuki","year":"2004","journal-title":"Oncol Rep"},{"key":"R21-20260812","doi-asserted-by":"crossref","first-page":"e0209486","DOI":"10.1371\/journal.pone.0209486","article-title":"Statin therapy in the treatment of active cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Farooqi","year":"2018","journal-title":"PLoS One"},{"key":"R22-20260812","first-page":"117\u201327","article-title":"Frailty in older adults with multiple myeloma: a study of US veterans","volume":"4","author":"Patel","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"R23-20260812","doi-asserted-by":"crossref","first-page":"32\u201340","DOI":"10.1016\/j.thromres.2024.01.016","article-title":"Risk of thromboembolism according to statin treatment in patients with cancer: a nationwide nested case-control study","volume":"235","author":"Yoo","year":"2024","journal-title":"Thromb Res"},{"key":"R24-20260812","doi-asserted-by":"crossref","first-page":"216\u201322","DOI":"10.1016\/j.acvd.2015.11.007","article-title":"Statins and prevention of venous thromboembolism: myth or reality?","volume":"109","author":"Gaertner","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"R25-20260812","doi-asserted-by":"crossref","first-page":"23\u201329","DOI":"10.1016\/j.biopha.2015.12.017","article-title":"Statins inhibited the MIP-1\u03b1 expression via inhibition of Ras\/ERK and Ras\/Akt pathways in myeloma cells","volume":"78","author":"Tsubaki","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"R26-20260812","doi-asserted-by":"crossref","first-page":"933\u201339","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"R27-20260812","doi-asserted-by":"crossref","first-page":"2536\u201347","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"Di Stefano","year":"2022","journal-title":"Haematologica"},{"key":"R28-20260812","doi-asserted-by":"crossref","first-page":"1176\u201384","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"R29-20260812","doi-asserted-by":"crossref","first-page":"2443\u201350","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"R30-20260812","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jamda.2019.06.027","article-title":"Effects of statins on relative risk of fractures for older adults: an updated systematic review with meta-analysis","volume":"20","author":"Shi","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"R31-20260812","doi-asserted-by":"crossref","DOI":"10.7727\/wimj.2014.227","article-title":"Simvastatin protects osteoblasts from the deleterious effects of the liquid milieu of multiple myeloma","author":"Jitumori","year":"2016","journal-title":"West Indian Med J"},{"key":"R32-20260812","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/ijms23031639","article-title":"Bone health in patients with dyslipidemias: an underestimated aspect","volume":"23","author":"Anagnostis","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R33-20260812","doi-asserted-by":"crossref","first-page":"743\u201352","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"R34-20260812","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R35-20260812","doi-asserted-by":"crossref","first-page":"1639130","DOI":"10.3389\/fmed.2025.1639130","article-title":"Statin use and acute kidney injury among hospitalized chronic kidney disease patients: a retrospective cohort study","volume":"12","author":"Tang","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"R36-20260812","doi-asserted-by":"crossref","first-page":"939\u201346","DOI":"10.1681\/ASN.2010050442","article-title":"Statin use associates with a lower incidence of acute kidney injury after major elective surgery","volume":"22","author":"Molnar","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R37-20260812","doi-asserted-by":"crossref","first-page":"1535\u201342","DOI":"10.1038\/sj.ki.5000300","article-title":"Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects","volume":"69","author":"Yasuda","year":"2006","journal-title":"Kidney Int"},{"key":"R38-20260812","doi-asserted-by":"crossref","first-page":"2086\u201392","DOI":"10.1053\/j.jvca.2017.04.038","article-title":"Perioperative statins do not prevent acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials","volume":"31","author":"Zhao","year":"2017","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R39-20260812","doi-asserted-by":"crossref","first-page":"1583\u201390","DOI":"10.1002\/pds.4898","article-title":"Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury","volume":"28","author":"Coste","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R40-20260812","doi-asserted-by":"crossref","first-page":"423\u201329","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"key":"R41-20260812","doi-asserted-by":"crossref","first-page":"1833\u201346","DOI":"10.1182\/blood.2019003807","article-title":"Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study","volume":"135","author":"Royal","year":"2020","journal-title":"Blood"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:40:10Z","timestamp":1786545610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005281","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-04-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}